Skip to main content
Premium Trial:

Request an Annual Quote

Baylor, Berry Genomics Team on Non-invasive Prenatal Dx

NEW YORK (GenomeWeb News) – Baylor College of Medicine said on Thursday that it will partner with the Chinese prenatal testing company Berry Genomics to combine their capabilities to improve prenatal genetic testing methods.

The partners plan to harness BCM's gene-chip microarray technologies that assess chromosome structure and Berry Genomics' technologies, which are used to evaluate fetal DNA in maternal plasma.

Testing using samples from fetal DNA from the mother's plasma gives patients the option of avoiding invasive procedures, such as placental or amniocentesis tests, which carry some risks and can be a source of stress for expecting mothers.

"We are conducting research to enable non-invasive prenatal testing to detect all the conditions currently detected by invasive testing," Arthur Beaudet, chair and professor of molecular genetics at BCM, said in a statement.

"Non-invasive prenatal testing and microarray technology are rapidly changing the way we detect genetic diseases," explained Berry Genomics' CEO Daixing Zhou, who added that this collaboration aims to enable them to "offer complete solutions for prenatal screening and diagnosis."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.